References

5.. Shields CL, Shields JA, Kiratli H, et al: Risk factors for growth and metastasis of small choroidal melanocytic lesions. Trans Am Ophthalmol Soc  1995; 93:259-275.

6.. Butler P, Char DH, Zarbin M, et al: Natural history of indeterminate pigmented choroidal tumors. Ophthalmology  1994; 101:710-716.

7.. Oosterhuis JA, Journee-de Korver HG, Kakebeeke-Kemme HM, et al: Transpupillary thermotherapy in choroidal melanomas. Arch Ophthalmol  1995; 113:315-321.

8.. Shields CL, Shields JA, Perez N, et al: Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: outcomes and limitations. Ophthalmology  2002; 109:225-234.

9.. Harbour JW, Meredith TA, Thompson PA, et al: Transpupillary thermotherapy versus plaque radiotherapy for suspected choroidal melanomas. Ophthalmology  2003; 110:2207-2214.

10.. Zaldivar RA, Aaberg TM, Sternberg Jr P, et al: Clinicopathologic findings in choroidal melanomas after failed transpupillary thermotherapy. Am J Ophthalmol  2003; 135:657-663.

11.. Finger PT: Microwave thermoradiotherapy for uveal melanoma: results of a 10-year study. Ophthalmology  1997; 104:1794-1803.

14.. Bergman L, Nilsson B, Lundell G, et al: Ruthenium brachytherapy for uveal melanoma, 1979–2003: survival and functional outcomes in the Swedish population. Ophthalmology  2005; 112:834-840.

15.. Lommatzsch PK: Results after beta-irradiation (106Ru/106Rh) of choroidal melanomas: 20 years’ experience. Br J Ophthalmol  1986; 70:844-851.

16.. Rouberol F, Roy P, Kodjikian L, et al: Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years’ experience with beta-rays). Am J Ophthalmol  2004; 137:893-900.

17.. van Ginderdeuren R, van Limbergen E, Spileers W: 18 years’ experience with high dose rate strontium-90 brachytherapy of small to medium sized posterior uveal melanoma. Br J Ophthalmol  2005; 89:1306-1310.

18.. Finger PT, Berson A, Ng T, et al: Palladium-103 plaque radiotherapy for choroidal melanoma: an 11-year study. Int J Radiat Oncol Biol Phys  2002; 54:1438-1445.

22.. Char DH: Metastatic choroidal melanoma. Am J Ophthalmol  1978; 86:76-80.

23.. Gragoudas ES, Lane AM, Munzenrider J, et al: Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma. Trans Am Ophthalmol Soc  2002; 100:43-48.

24.. Char DH, Saunders W, Castro JR, et al: Helium ion therapy for choroidal melanoma. Ophthalmology  1983; 90:1219-1225.

25.. Kodjikian L, Roy P, Rouberol F, et al: Survival after proton-beam irradiation of uveal melanomas. Am J Ophthalmol  2004; 137:1002-1010.

26.. Gragoudas E, Li W, Goitein M, et al: Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol  2002; 120:1665-1671.

27.. Gragoudas ES, Li W, Lane AM, et al: Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. Ophthalmology  1999; 106:1571-1577.

28.. Gragoudas ES, Lane AM, Regan S, et al: A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. Arch Ophthalmol  2000; 118:773-778.

29.. Egan KM, Gragoudas ES, Seddon JM, et al: The risk of enucleation after proton beam irradiation of uveal melanoma. Ophthalmology  1989; 96:1377-1382.

33.. Foulds WS: The local excision of choroidal melanomata. Trans. Ophthalmol Soc UK  1973; 93:343-346.

34.. Damato BE, Paul J, Foulds WS: Risk factors for residual and recurrent uveal melanoma after trans-scleral local resection. Br J Ophthalmol  1996; 80:102-108.

35.. Zehetmayer M, Kitz K, Menapace R, et al: Local tumor control and morbidity after one to three fractions of stereotactic external beam irradiation for uveal melanoma. Radiother Oncol  2000; 55:135-144.

36.. Simonova G, Novotny Jr J, Liscak R, et al: Leksell gamma knife treatment of uveal melanoma. J Neurosurg  2002; 97(Suppl.):635-639.

37.. Fakiris AJ, Lo SS, Henderson MA, et al: Gamma-knife-based stereotactic radiosurgery for uveal melanoma. Stereotact Funct Neurosurg  2007; 85:106-112.

38.. Garbe C, Eigentler TK: Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res  2007; 17:117-127.

39.. Callejo SA, Antecka E, Blanco PL, et al: Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study. Eye  2007; 21:752-759.

40.. Prescher G, Bornfeld N, Hirche H, et al: Prognostic implications of monosomy 3 in uveal melanoma. Lancet  1996; 347:1222-1225.

41.. Prescher G, Bornfeld N, Becher R: Nonrandom chromosomal abnormalities in primary uveal melanoma. J Natl Cancer Inst  1990; 82:1765-1769.

42.. Aalto Y, Eriksson L, Seregard S, et al: Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci  2001; 42:313-317.

43.. Sisley K, Parsons MA, Garnham J, et al: Association of specific chromosome alterations with tumour phenotype in posterior uveal melanoma. Br J Cancer  2000; 82:330-338.